Funding for this research was provided by:
University of Occupational and Environmental Health (H29-903,H30-905)
Japan Agency for Medical Research and Development
Ministry of Education, Culture, Sports, Science and Technology
Ministry of Health, Labour and Welfare of Japan
Received: 22 July 2019
Accepted: 23 January 2020
First Online: 12 February 2020
Ethics approval and consent to participate
: Ethical approval was obtained from the University of Occupational and Environmental Health, Japan Ethics Committee.
: Not applicable
: YT has received consulting fees, speaking fees, and/or honoraria from Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, and UCB, and has received research grants from Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa-Kirin, Eisai, and Ono. SN has received speaking fees from Bristol-Myers, UCB, Astellas, Abbvie, Eisai, Pfizer, and Takeda, and has received research grants from Mitsubishi-Tanabe, Novartis, and MSD. KY has received research grants from Mitsubishi-Tanabe. SH has received speaking fee and honoraria from AbbVie, Asahi-Kasei Pharma, Astellas, Ayumi, Bristol-Myers Squibb, Celgene, Chugai, Eisai, Eli Lilly, Janssen, Kissei, Novartis, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. NB is an employee of Augurex. All other authors declare that they have no competing interests.